![Expert Q&A: Full Approval for Alzheimer’s Blood Tests Not Far Off](https://www.g2intelligence.com/wp-content/uploads/2024/05/June24.CDI_.Expert-Q-A.AndreasJeromin.RMV-iStock-1100x800-1-1080x675.jpg)
Expert Q&A: Full Approval for Alzheimer’s Blood Tests Not Far Off
Andreas Jeromin, PhD, chief scientific officer at ALZPath, discusses the current landscape of blood-based AD tests and their future.
Andreas Jeromin, PhD, chief scientific officer at ALZPath, discusses the current landscape of blood-based AD tests and their future.
Alison Green, PhD, head of laboratory sciences at Scottish Brain Sciences, discusses recent developments in AD blood tests
A new capillary blood collection system, the BD MiniDraw™, can improve the testing experience for both labs and patients
Examining what led to record low BB/TM ABPath certification examination pass rates in 2022
Publishing peer-reviewed studies to tout the economic benefits of medical devices is fairly commonplace, but rare for a laboratory company
Examining DOJ and OIG investigations of labs and their owners: Recent cases show continued focus on the usual enforcement targets.
Laboratory diagnostics manufacturers receive regulatory scrutiny for issues including marketing, quality, and unapproved changes to tests
Key steps to follow when selling your lab to ensure compliance with the Eliminating Kickbacks in Recovery Act of 2018 (EKRA)
When selling your laboratory, in order to remain compliant with federal code, EKRA is something you will want to consider
Outreach and advertising can be tricky prospects for the clinical lab—but the right questions and strategies can help guide your efforts